Prof Workman talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium, explaining what molecular chaperones are and their role in causing cancer. He discusses the first generation of Hsp90 (Heat Shock Protein 90) inhibitors and the ICR’s creation of a 2nd generation of Hsp90 inhibitors, e.g.  NVP-AUY922, currently in a phase II trials. Prof Workman also looks to the future of the 3rd generation of Hsp90 inhibitors. A recent phase I trial has also discovered a clear clinical link between ErbB-2 (HER2/neu ) positive breast cancer and regression after treatment with an Hsp90 inhibitor (for patients that have become refractory to Herceptin (trustuzamab). Toxicities are also covered.